Please assess the completion status of the following clinical trial:

Trial Title: Noctura400 Treatment for Diabetic Retinopathy (CANDLE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~i. Subjects of either sex aged 18 years or over. ii. Diagnosis of diabetes mellitus (type 1 or type 2). iii. Presence of clinically significant centre-involving macular oedema resultant from DR of ≥400µm (CST/CMT as measured by OCT, and is listed for ranibizumab therapy in the study eye.~Exclusion Criteria:~Any potential participant will be excluded if they have:~i. Received any previous anti-VEGF/steroid intravitreal injections in the study eye in the last 6 months.~ii. Presence of proliferative diabetic retinopathy (PDR) at screening.~iii. Significant systemic diseases know to affect visual function, other than diabetes (e.g. Parkinson's disease or Alzheimer's disease).~iv. History of relevant sleeping disorders/insomnia .~v. A condition that would preclude participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Standard Arm (Type: ACTIVE_COMPARATOR): Those receiving only their prescribed ranibizumab treatment only
- Intervention Arm (Type: EXPERIMENTAL): Noctura 400 Eye Mask in conjunction with their prescribed ranibizumab treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).